Wire · opportunities
The AI Moment in Drug Discovery: Daphne Koller on The Long Run
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Insitro, led by Daphne Koller, uses AI to accelerate drug discovery by leveraging curated biological data, aiming to improve outcomes in clinical trials for diseases like fatty liver disease and ALS. The company has attracted $750 million in funding from venture capital and partnerships with major pharma companies.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
You face a fast-moving shift as AI reaches meaningful impact in drug discovery beyond data gathering, especially in developing treatments for complex diseases. Building relationships with AI-driven drug developers like Insitro could unlock early access to more predictive preclinical models and shorten your clinical timelines.
◆ Coverage
1 source · 3 Nov 2026
◆ Related on Wire
◆ Topics